Oral dosage forms favor good patient acceptance and compliance in great part because they are easy to take. However, achieving sufficient bioavailability by the oral route can be challenging due to the complexity of the gastrointestinal (GI) tract.
Oral bioavailability of therapeutic substances is governed by their intrinsic properties, notably solubility in aqueous media and ability to permeate the intestinal barrier.
About 95% of new molecular entities are small moleculesa (i.e. organic compounds with low molecular weight). Of these, 80% fall in the BCS II and 20% in BCS IV categories for which oral bioavailability is challenged by poor solubility in aqueous GI environment. The use of lipid-based formulations (LBF) as drug delivery system is a well-known strategy to overcome this limitation and increase in vivo drug exposure.
Please fill out the information below to request information on the products you selected. If you are already registered, or have requested a quote before, login and this information will be filled out for you.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.
Please enter the phone number you would like to be contacted at.
By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information, transmitting your contact information to selected trusted partners, and customizing your experience based on the data you enter. You can also stay up-to-date on the latest news, new technologies, and more delivered to your email inbox by selecting your subscription preferences on the next page.